
Mount Sinai Researchers Explain Biobanks Used in Clinical Variants Study
Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain the differences between the biobanks used in their study on population-based penetrance of clinical variants.
Ron Do, PhD, associate professor, Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai, and Iain Forrest, MD-PhD candidate in Dr Do’s lab, explain the differences between the biobanks used in their study on population-based penetrance of clinical variants.
Transcript
Your study used 2 biobanks that are a bit different from each other in terms of populations. What are the pros and cons of each?
Do: Just to recap, this study used 2 biobanks. The first was the BioMe Biobank, which was comprised of Mount Sinai patients recruited from the Mount Sinai Health System in and around New York City. Because of this, these individuals had a higher burden of diseases.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.